Currently, Monopar Therapeutics Inc [MNPR] is trading at $17.83, up 5.32%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MNPR shares have gain 239.62% over the last week, with a monthly amount glided 163.37%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Monopar Therapeutics Inc [NASDAQ: MNPR] stock has seen the most recent analyst activity on October 11, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $50. Previously, ROTH Capital started tracking the stock with Buy rating on January 28, 2021, and set its price target to $49.
This stock has fluctuated between a low of $1.37 and a high of $38.50 over the last 52 weeks. Monopar Therapeutics Inc [NASDAQ: MNPR] shares were valued at $17.83 at the most recent close of the market.
Analyzing the MNPR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.99, Equity is -1.11 and Total Capital is -1.23.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.30 points at the first support level, and at 10.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.65, and for the 2nd resistance point, it is at 25.48.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Monopar Therapeutics Inc [NASDAQ:MNPR] is 6.59. Also, the Quick Ratio is 6.59, while the Cash Ratio stands at 5.62.
Transactions by insiders
Recent insider trading involved Cittadine Andrew, Chief Operating Officer, that happened on Jun 20 ’24 when 20508.0 shares were purchased. Chief Operating Officer, Cittadine Andrew completed a deal on Jun 18 ’24 to buy 12000.0 shares. Meanwhile, Chief Operating Officer Cittadine Andrew bought 12000.0 shares on Jun 14 ’24.
